These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31006110)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
    Desta Z; Gammal RS; Gong L; Whirl-Carrillo M; Gaur AH; Sukasem C; Hockings J; Myers A; Swart M; Tyndale RF; Masimirembwa C; Iwuchukwu OF; Chirwa S; Lennox J; Gaedigk A; Klein TE; Haas DW
    Clin Pharmacol Ther; 2019 Oct; 106(4):726-733. PubMed ID: 31006110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
    Haas DW; Severe P; Jean Juste MA; Pape JW; Fitzgerald DW
    J Antimicrob Chemother; 2014 Aug; 69(8):2187-90. PubMed ID: 24695352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
    Torgersen J; Bellamy SL; Ratshaa B; Han X; Mosepele M; Zuppa AF; Vujkovic M; Steenhoff AP; Bisson GP; Gross R
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):179-187. PubMed ID: 30168000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
    van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
    Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
    Haas DW; Acosta EP
    Clin Infect Dis; 2021 May; 72(10):1820-1822. PubMed ID: 32667979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.
    Vo TT; Varghese Gupta S
    Pharmacotherapy; 2016 Dec; 36(12):1245-1254. PubMed ID: 27779789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.
    Eniayewu O; Azuka U; Ogah J; Adejuyigbe E; Bolaji O; Olagunju A
    Clin Pharmacol Ther; 2024 Oct; 116(4):1062-1070. PubMed ID: 38859656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
    Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
    Meng XM; Li ZR; Zheng XY; Liu YX; Niu WJ; Qiu XY; Lu HZ
    Eur J Pharm Sci; 2021 Dec; 167():105986. PubMed ID: 34474119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.